[96a5a0]: / output / allTrials / identified / NCT00718562_identified.json

Download this file

290 lines (290 with data), 11.6 kB

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
{
"info": {
"nct_id": "NCT00718562",
"official_title": "A Multi-center Phase II Study to Evaluate the Efficacy and Safety of AMN107 (Nilotinib) in Patients With Gastrointestinal Stromal Tumors Who Have Progressed on or Are Intolerant to Both Imatinib and Sunitinib",
"inclusion_criteria": "* Documented disease progression during imatinib and sunitinib therapy OR intolerance to imatinib and/or sunitinib\n* At least one measurable site of disease on CT/MRI scan\n* PS≤2\n* Normal organ, electrolyte, and bone marrow function\nHealthy volunteers allowed\nMust have minimum age of 20 Years",
"exclusion_criteria": "* Previous treatment with nilotinib or any other drug in this class or other targeted therapy\n* Treatment with any cytotoxic and/or investigational drug ≤ 4 weeks prior to study entry\n* Impaired cardiac function\n* Use of coumarin derivatives (i.e. warfarin)\n* Women who are pregnant or lactating\n\nOther protocol-defined inclusion/exclusion criteria may apply.",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"line": "* Documented disease progression during imatinib and sunitinib therapy OR intolerance to imatinib and/or sunitinib",
"criterions": [
{
"exact_snippets": "Documented disease progression during imatinib and sunitinib therapy",
"criterion": "disease progression",
"requirements": [
{
"requirement_type": "documentation",
"expected_value": true
},
{
"requirement_type": "during therapy",
"expected_value": [
"imatinib",
"sunitinib"
]
}
]
},
{
"exact_snippets": "intolerance to imatinib and/or sunitinib",
"criterion": "intolerance",
"requirements": [
{
"requirement_type": "medication",
"expected_value": [
"imatinib",
"sunitinib"
]
}
]
}
]
},
{
"line": "* At least one measurable site of disease on CT/MRI scan",
"criterions": [
{
"exact_snippets": "At least one measurable site of disease on CT/MRI scan",
"criterion": "measurable site of disease",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": ">=",
"value": 1,
"unit": "site"
}
},
{
"requirement_type": "detection method",
"expected_value": [
"CT scan",
"MRI scan"
]
}
]
}
]
},
{
"line": "* PS≤2",
"criterions": [
{
"exact_snippets": "PS≤2",
"criterion": "performance status",
"requirements": [
{
"requirement_type": "severity",
"expected_value": {
"operator": "<=",
"value": 2,
"unit": "N/A"
}
}
]
}
]
},
{
"line": "* Normal organ, electrolyte, and bone marrow function",
"criterions": [
{
"exact_snippets": "Normal organ",
"criterion": "organ function",
"requirements": [
{
"requirement_type": "functionality",
"expected_value": "normal"
}
]
},
{
"exact_snippets": "Normal ... electrolyte",
"criterion": "electrolyte function",
"requirements": [
{
"requirement_type": "functionality",
"expected_value": "normal"
}
]
},
{
"exact_snippets": "Normal ... bone marrow function",
"criterion": "bone marrow function",
"requirements": [
{
"requirement_type": "functionality",
"expected_value": "normal"
}
]
}
]
},
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must have minimum age of 20 Years",
"criterions": [
{
"exact_snippets": "minimum age of 20 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 20,
"unit": "Years"
}
}
]
}
]
}
],
"exclusion_lines": [
{
"line": "* Previous treatment with nilotinib or any other drug in this class or other targeted therapy",
"criterions": [
{
"exact_snippets": "Previous treatment with nilotinib",
"criterion": "previous treatment with nilotinib",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "Previous treatment with ... any other drug in this class",
"criterion": "previous treatment with any other drug in the same class as nilotinib",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "Previous treatment with ... other targeted therapy",
"criterion": "previous treatment with other targeted therapy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "* Treatment with any cytotoxic and/or investigational drug ≤ 4 weeks prior to study entry",
"criterions": [
{
"exact_snippets": "Treatment with any cytotoxic and/or investigational drug ≤ 4 weeks prior to study entry",
"criterion": "treatment with cytotoxic and/or investigational drug",
"requirements": [
{
"requirement_type": "time since last treatment",
"expected_value": {
"operator": "<=",
"value": 4,
"unit": "weeks"
}
}
]
}
]
},
{
"line": "* Impaired cardiac function",
"criterions": [
{
"exact_snippets": "Impaired cardiac function",
"criterion": "cardiac function",
"requirements": [
{
"requirement_type": "condition",
"expected_value": "impaired"
}
]
}
]
},
{
"line": "* Use of coumarin derivatives (i.e. warfarin)",
"criterions": [
{
"exact_snippets": "Use of coumarin derivatives (i.e. warfarin)",
"criterion": "coumarin derivatives",
"requirements": [
{
"requirement_type": "use",
"expected_value": true
}
]
}
]
},
{
"line": "* Women who are pregnant or lactating",
"criterions": [
{
"exact_snippets": "Women who are pregnant",
"criterion": "pregnancy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "Women who are ... lactating",
"criterion": "lactation",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "Other protocol-defined inclusion/exclusion criteria may apply.",
"criterions": [
{
"exact_snippets": "Other protocol-defined inclusion/exclusion criteria",
"criterion": "protocol-defined criteria",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
}
],
"miscellaneous_lines": [],
"failed_inclusion": [],
"failed_exclusion": [],
"failed_miscellaneous": []
}